natgillin/translations-raw huggingface dataset:
The primary endpoint of the study was corticosteroid-free clinical remission at week 26, defined as patients in clinical remission (CDAI of &lt; 150) who, for at least 3 weeks, had not taken oral systemic corticosteroids (prednisone or equivalent) or budesonide at a dose &gt; 6 mg/day.
Primarna mjera ishoda ispitivanja bila je klinička remisija bez primjene kortikosteroida u 26. tjednu, što je značilo da bolesnik u kliničkoj remisiji (CDAI &lt; 150) najmanje 3 tjedna nije uzimao peroralne sustavne kortikosteroide (prednizon ili slično) ni budezonid u dozi od &gt; 6 mg/dan.
The primary endpoint of the study was met: a statistically significantly higher percentage of subjects in the Resolor group (37.9%) had an average of ≥ 3 SCBMs/week compared with subjects in the placebo treatment group (17.7%) (p &lt; 0.0001) over the 12-week double-blind treatment period.
Postignut je primarni ishod ispitivanja: statistički značajno viši postotak ispitanika u skupini liječenoj lijekom Resolor (37,9%) imao je prosječno ≥3 kompletnih pražnjenja crijeva na tjedan, u usporedbi s ispitanicima u skupini koja je liječena placebom (17,7%) (p &lt; 0,0001) u 12-tjednom, dvostruko slijepom razdoblju liječenja.
The primary endpoint of the study was post-transplant virologic response (pTVR, HCV RNA &lt; LLOQ at 12 weeks post-transplant).
Primarni ishod ispitivanja bio je virološki odgovor nakon transplantacije (pTVR, HCV RNK &lt; donje granice kvantifikacije u 12. tjednu nakon transplantacije).
The primary endpoint of therapeutic response was a composite serological endpoint requiring suppression of HBV DNA to &lt; 5 log10 copies/ml in conjunction with either loss of serum HBeAg or ALT normalised.
Primarna mjera ishoda terapijskog odgovora bila je kompozitna serološka mjera ishoda koja se sastoji od supresije HBV DNK do &lt; 5 log10 kopija/ml u kombinaciji ili s nestankom serumskog HBeAg ili s normalizacijom ALT-a.
The primary endpoint was the comparison between the summed pain intensity difference at 30 minutes after dosing (SPID30), which was 6.57 in the PecFent-treated episodes compared to 4.45 for placebo (p &lt; 0.0001 ).
Superiornost je dokazana primarnim ishodom, razlikom intenziteta bola unutar 15 minuta, koja je u bolesnika liječenih PecFentom iznosila 3,02 u usporedbi s 2,69 u bolesnika liječenih morfin sulfatom s trenutačnim otpuštanjem (p=0,0396).
The primary endpoint was the frequency of clinically significant exacerbations of asthma and the reductions for both mepolizumab treatment arms compared to placebo were statistically significant (p &lt; 0.001).
Primarna mjera ishoda bila je učestalost klinički značajnih egzacerbacija astme i smanjenja su u obje skupine liječene mepolizumabom bila statistički značajna u odnosu na placebo (p &lt; 0,001).
The primary endpoint was the proportion of patients achieving DAS28 remission (DAS28 &lt; 2.6) at week 24.
Primarna mjera ishoda bio je udio bolesnika koji su postigli remisiju DAS28 (DAS28 &lt; 2,6) u 24. tjednu.
The primary endpoint was the rate of patients with complete asparagine depletion in serum (defined as asparagine serum levels below the lower limit of quantification ( &lt; 0.5 µM) at all time points measured from day 12 up to day 33) during induction treatment.
Primarni ishod bila je stopa bolesnika s potpunom deplecijom asparagina u serumu (definirano kao serumske razine asparagina ispod donje granice kvantifikacije ( &lt; 0,5 µM) u svim vremenskim točkama mjereno od 12. do 33. dana) tijekom indukcijskog liječenja.
The primary objective assessed the incidence of Grade 3 and 4 ALT abnormalities ( &gt; 5x upper limit of normal (ULN) if baseline ALT ≤ ULN; or &gt; 3.5x baseline if baseline ALT &gt; ULN) at Week 48.
Primarni cilj bio je procjena incidencije odstupanja ALT-a stupnja 3 i 4 ( &gt; 5x od gornje granice normale (GGN) ako je početni ALT ≤ GGN; ili &gt; 3,5x početna vrijednost ako je početni ALT &gt; GGN) u 48. tjednu.
The primary objective of this study was to compare the proportion of patients whose SeDBP was controlled (SeDBP &lt; 90 mmHg) at Week 5 of treatment.
Primarni cilj ispitivanja bio je usporediti omjer bolesnika čiji je dijastolički krvni tlak u sjedećem položaju bio kontroliran ( &lt; 90 mmHg) u 5. tjednu liječenja.
The primary objective of this study was to compare the proportion of patients whose SeDBP was controlled (SeDBP &lt; 90 mmHg) at Week 5 of treatment.
Primarni cilj ispitivanja bio je usporediti udio bolesnika čiji je dijastolički krvni tlak u sjedećem položaju bio kontroliran ( &lt; 90 mmHg) u 5. tjednu liječenja.
The primary objective of this study was to compare the proportion of patients whose SeDBP was controlled (SeDBP &lt; 90 mmHg) at Week 5 of treatment.
Primarni cilj studije bio je usporediti omjer bolesnika čiji je dijastolički krvni tlak u sjedećem položaju bio kontroliran ( &lt; 90 mmHg) u 5. tjednu liječenja.
The primary outcome parameter was the time to sputum culture conversion (i.e. the interval between the first SIRTURO intake and the first of two consecutive negative liquid cultures from sputum collected at least 25 days apart) during treatment with SIRTURO or placebo (median time to conversion was 83 days for the SIRTURO group, 125 days for the placebo group (hazard ratio, 95% CI: 2.44 [1.57; 3.80]), p &lt; 0.0001).
Primarni parametar ishoda bilo je vrijeme do konverzije kulture sputuma (tj. interval između prvog uzimanja lijeka SIRTURO i prve od dvije uzastopne negativne tekuće kulture iz sputuma koje su prikupljene u razmaku od najmanje 25 dana) tijekom liječenja lijekom SIRTURO ili placebom (medijan vremena do konverzije bio je 83 dana za skupinu liječenu lijekom SIRTURO, 125 dana za placebo skupinu (omjer hazarda, 95% CI: 2,44 [1,57; 3,80]), p &lt; 0,0001).
The primary route of elimination of elbasvir and grazoprevir is through faeces with almost all ( &gt; 90 %) of the radiolabeled dose recovered in faeces compared to &lt; 1 % in urine.
Primarni put eliminacije elbasvira i grazoprevira je putem fecesa; gotovo je sva ( &gt; 90%) radioaktivno označena doza pronađena u fecesu, dok je u mokraći pronađeno &lt; 1% doze.
The primary support for safety and efficacy of Xolair in the group aged 6 to &lt; 12 years comes from one randomised, double-blind, placebo-controlled, multi-centre trial (study 7).
Primarni podaci koji podupiru sigurnost i djelotvornost Xolaira u skupini od 6 do &lt; 12 godina starosti dolaze iz jednog randomiziranog, dvostruko slijepog, placebom kontroliranog multicentričnog ispitivanja (studija 7).
The primary variable of interest was the occurrence of ventricular pauses ≥3 seconds.
Primarna varijabla od interesa bila je pojava ventrikularnih stanki &gt; 3 sekunde.
The principle route of excretion in dogs is via the bile ( &gt; 80%) with the remainder via the urine.
Glavni put izlučivanja u pasa je putem žuči ( &gt; 80 %), dok se preostala količina izlučuje urinom.
The product causes a long-lasting inhibition of plasma ACE activity in dogs, with more than 95% inhibition at peak effect and significant activity ( &gt; 80%) persisting 24 hours after dosing.
Proizvod uzrokuje dugotrajnu inhibiciju plazmatske aktivnosti ACE u pasa s više od 95% inhibicije na vrhuncu učinka i značajnom aktivnosti ( &gt; 80%) koja traje 24 sata nakon doziranja.
The proportion of patients achieving a complete haematological remission was 23.6% on Jakavi compared to 8.9% on BAT (p=0.0028) and the proportion of patients achieving a durable primary response at week 48 was 19.1% on Jakavi and 0.9% on BAT.(p &lt; 0.0001).
Udio bolesnika koji su postigli kompletnu hematološku remisiju bio je 23,6% na Jakaviju u usporedbi s 8,9% na NDT-u (p=0,0028), a udio bolesnika koji su postigli trajan primarni odgovor u 48. tjednu bio je 19,1% na Jakaviju i 0,9% na NDT-u (p &lt; 0,0001).
The proportion of patients achieving a DAS28 clinical remission (DAS28 &lt; 2.6) was significantly higher in patients receiving tocilizumab (28–34%) compared to 1–12% of control patients at 24 weeks.
Udio bolesnika koji su postigli kliničku remisiju prema DAS28 (DAS28 &lt; 2,6) bio je značajno viši u skupini koja je primala tocilizumab (28-34%) nego u kontrolnoj skupini (1-12%) nakon 24 tjedna.
The proportion of patients achieving biochemical control was 15.4% (p-value = 0.0006) and 20.0% (p-value &lt; 0.0001) for pasireotide intramuscular use 40 mg and 60 mg, respectively at 24 weeks compared with zero in the active control arm (Table 3).
Udio bolesnika koji su postigli biokemijsku kontrolu bio je 15,4% (p-vrijednost = 0,0006) odnosno 20,0% (p-vrijednost &lt; 0,0001) za pasireotid 40 mg odnosno 60 mg intramuskularno u 24. tjednu, u usporedbi s nula u skupini s aktivnom kontrolom (Tablica 3).
The proportion of patients achieving HbA1c &lt; 7 % at week 24 for add-on therapy with dapagliflozin to saxagliptin plus metformin trial was higher in the saxagliptin plus dapagliflozin plus metformin group 35.3 % (95 % CI [28.2, 42.2]) compared to the placebo plus dapagliflozin plus metformin group 23.1 % (95 % CI [16.9, 29.3]).
Udio bolesnika koji su postigli HbA1c &lt; 7 % u 24. tjednu ispitivanja dapagliflozina kao dodatne terapije uz saksagliptin plus metformin bio je veći u skupini koja je primala saksagliptin plus dapagliflozin plus metformin i iznosio 35,3% [95% CI: 28,2; 42,2]) u usporedbi sa skupinom koja je primala placebo plus dapagliflozin plus metformin, gdje je bio 23,1% [95% CI: 16,9; 29,3]).
The proportion of patients achieving HbA1c &lt; 7% and HbA1c ≤ 6.5% was 56% and 42% with immediate-release exenatide and 29% and 13% with placebo.
Uz eksenatid s trenutnim oslobađanjem je 56% bolesnika postiglo vrijednosti HbA1c od &lt; 7%, a 42% vrijednosti od ≤ 6,5%, dok je uz placebo navedene vrijednosti postiglo 29% odnosno 13% bolesnika.
The proportion of patients achieving HbA1c &lt; 7% was 47.9% with immediate-release exenatide and 42.8% with insulin lispro.
Postotak bolesnika koji su ostvarili HbA1c &lt; 7% bio je 47,9% sa eksenatidom s trenutnim oslobađanjem te 42,8% sa inzulinom lispro.
The proportion of patients achieving HbA1c &lt; 7.0 % at Week 24 in the add-on therapy with saxagliptin to dapagliflozin plus metformin trial was higher in the saxagliptin plus dapagliflozin plus metformin group 38.0 % (95 % CI [30.9, 45.1]) compared to the placebo plus saxagliptin plus metformin group 12.4 % (95 % CI [7.0, 17.9]).
Udio bolesnika koji su postigli HbA1c &lt; 7,0% u 24. tjednu ispitivanja u kojem se saksagliptin primjenjivao kao dodatna terapija uz dapagliflozin i metformin, bio je veći u skupini koja je primala saksagliptin plus dapagliflozin plus metformin i iznosio 38,0% [95% CI: 30,9; 45,1]) u usporedbi sa skupinom koja je primala placebo plus saksagliptin plus metformin, gdje je bio 12,4% [95% CI: 7,0;
The proportion of patients achieving viral load of &lt; 400 copies/ml at week 48 was 30.4% among patients on the Fuzeon + OB regimen compared to 12% among patients receiving OB regimen only.
Udio bolesnika koji su u 48. tjednu postigli virusno opterećenje od &lt; 400 kopija/ml iznosio je 30,4% u bolesnika koji su primali Fuzeon + OT u usporedbi s 12% u bolesnika koji su primali samo OT.
The proportion of patients having an RFBM within 4 hours of the first dose was 34.2% in the combined methylnaltrexone bromide group versus 9.9% in the placebo group (p &lt; 0.001).
Udio bolesnika s pražnjenjem crijeva bez primjene dodatnog laksativa, unutar 4 sata od prve doze iznosio je 34,2% u kombiniranoj skupini s metilnaltreksonbromidom naspram 9,9% u placebo skupini (p &lt; 0,0001).
The proportion of patients with at least 15 letters improvement from baseline BCVA in the study eye at week 8 was more than 6-fold higher with OZURDEX (42.9%) compared to
Udio bolesnika s poboljšanjem od barem 15 slova u odnosu na početne vrijednosti BCVA u ispitivanom oku u 8. tjednu bio je više od 6 puta veći s lijekom OZURDEX (42,9%) u usporedbi s placebo postupkom (6,6%), p &lt; 0,001.
The proportion of patients with HIV-1 RNA &lt; 50 copies/mL at Week 48 (TLOVR) was 72.2% (26/36).
Udio bolesnika s HIV-1 RNK &lt; 50 kopija/ml u 48. tjednu (TLOVR) bio je 72,2% (26/36).
The proportion of patients with larger decreases in eGFR ( &gt; 30%) at any time during treatment was 9.3%, 12.2%, and 4.9% with canagliflozin 100 mg, canagliflozin 300 mg, and placebo, respectively.
Udio bolesnika s većim smanjenjima eGFR ( &gt; 30%) u bilo kojem trenutku tijekom liječenja kanagliflozinom od 100 mg, kanagliflozinom od 300 mg, odnosno placebom bio je 9,3%; 12,2% i 4,9%.
The proportion of patients with serum urate levels of &lt; 6.0 mg/dL (357 µmol/L) at the final visit, was 45% for 40 mg febuxostat, 67% for febuxostat 80 mg and 42% for allopurinol 300/200 mg, respectively.
Udio bolesnika s razinom urata u serumu &lt; 6,0 mg/dl (357 µmol/l) na završnoj kontroli bio je 45% za febuksostat od 40 mg, 67% za febuksostat od 80 mg i 42% za alopurinol od 300/200 mg.
The proportion of patients with serum urate levels of &lt; 6.0 mg/dL (357 µmol/L) at the final visit was greater than 80% (81-100%) at each febuxostat dose.
Udio bolesnika s razinom urata u serumu nižom od 6,0 mg/dl (357 µmol/l) na zadnjoj kontroli bio je veći od 80% (81-100%) kod svake doze febuksostata.
The proportion of responders was higher in subjects with a baseline viral load ≤ 100,000 copies/mL (78.6%, 22/28) as compared to those with a baseline viral load &gt; 100,000 copies/mL (50.0%, 4/8).
Udio bolesnika s odgovorom bio je veći u ispitanika s početnim virusnim opterećenjem ≤ 100 000 kopija/ml (78,6%, 22/28) u usporedbi s onima s početnim virusnim opterećenjem &gt; 100 000 kopija/ml (50,0%, 4/8).
The proportion of simeprevir-treated patients with HCV RNA &lt; 25 IU/ml detectable at week 4 was 14% (70/509); 67% achieved SVR12.
Udio bolesnika liječenih simeprevirom s HCV RNK &lt; 25 IU/ml koja je bila detektabilna u 4. tjednu bio je 14% (70/509); 67% postiglo je SVR12.
The proportion of simeprevir-treated patients with HCV RNA &lt; 25 IU/ml detectable at week 4 was 18% (47/259); 60% achieved SVR12.
Udio bolesnika liječenih simeprevirom s HCV RNK &lt; 25 IU/ml detektabilnom u 4. tjednu bio je 18% (47/259); 60% postiglo je SVR12.
The proportion of subjects experiencing adverse events (AE) and serious adverse events (SAE) was similar in the subjects aged &lt; 65 years and those aged ≥65 years.
Udio ispitanika u kojih su se pojavili štetni događaji i ozbiljni štetni događaji bio je sličan i među ispitanicima mlađima od 65 godina i među onima u dobi ≥ 65 godina.
The proportion of subjects who received a transfusion for the management of anaemia was 3% of subjects in the Victrelis-containing arms compared to &lt; 1% of subjects receiving peginterferon alfa-2b and ribavirin alone.
Udio bolesnika koji su primili transfuziju za liječenje anemije bio je 3% u skupinama ispitanika koji su primali Victrelis te &lt; 1% u skupinama koje su primale samo peginterferon alfa-2b i ribavirin.
The proportion of subjects with HIV-1 RNA &lt; 50 copies/mL at week 48 (TLOVR) was 72.2% (26/36).
Udio ispitanika s HIV-1 RNA &lt; 50 kopija/ml u 48. tjednu (TLOVR) bio je 72,2% (26/36).
The proportion of subjects with measurable disease at baseline who had an objective response was 36% in the ZYTIGA group and 16% in the placebo group (p &lt; 0.0001).
Udio ispitanika s mjerljivom bolesti na početku, koji su imali objektivni odgovor bio je 36% u skupini s lijekom ZYTIGA i 16% u placebo skupini (p &lt; 0.0001).
The proportion of virologic failures was lower in subjects with a baseline viral load ≤ 100,000 copies/mL (17.9%, 5/28) as compared to those with a baseline viral load &gt; 100,000 copies/mL (37.5%, 3/8).
Udio viroloških nesupjeha bio je niži u ispitanika s početnim virusnim opterećenjem ≤ 100 000 kopija/ml (17,9%, 5/28) u usporedbi s onima s početnim virusnim opterećenjem &gt; 100 000 kopija/ml (37,5%, 3/8).
The proportion was significantly larger than observed with insulin degludec (40.9%, odds ratio 2.28, p &lt; 0.0001) and similar to that observed with liraglutide (57.7%, odds ratio 1.13, p=0.3184).
Taj je udio bio značajno veći nego onaj primijećen s degludek inzulinom (40,9%; omjer šansi: 2,28; p &lt; 0,0001), a sličan onome primijećenom s liraglutidom (57,7%; omjer šansi: 1,13; p = 0,3184).
The proportions of patients with genotype 1, 2, 3, 4 or 6 HCV were 78%, 4%, 15%, 3%, and &lt; 1% (1 patient), respectively.
Udjeli bolesnika s genotipom 1, 2, 3, 4 ili 6 HCV-a bili su 78 %, 4 %, 15 %, 3 %, odnosno &lt; 1 % (1 bolesnik).
The proportions of patients with mucosal healing at week 26 were significantly greater in the infliximab plus AZA combination (43.9%, p &lt; 0.001) and infliximab monotherapy groups (30.1%, p = 0.023) compared to the AZA monotherapy group (16.5%).
Udio bolesnika kojima je sluznica zacijelila u 26. tjednu bio je značajno veći u skupini koja je primala infliksimab + AZA (43,9%, p &lt; 0,001) i skupini koja je primala monoterapiju infliksimabom (30,1%, p = 0,023) nego u skupini koja je primala monoterapiju AZA (16,5%).
The proportions of patients with mucosal healing at week 26 were significantly greater in the infliximab plus AZA combination (43.9%, p &lt; 0.001) and infliximab monotherapy groups (30.1%, p=0.023) compared to the AZA monotherapy group (16.5%).
Udio bolesnika kojima je sluznica zacijelila u 26. tjednu bio je značajno veći u skupini koja je primala infliksimab + AZA (43,9%, p &lt; 0,001) i skupini koja je primala monoterapiju infliksimabom (30,1%, p = 0,023) nego u skupini koja je primala monoterapiju AZA (16,5%).
The protein binding of simvastatin and its active metabolite is &gt; 95%.
&gt; 95% simvastatina i njegovih aktivnih metabolita veže se za proteine plazme.
The protocol specified analysis of investigator-assessed PFS (without censoring for CA-125 progression or non-protocol therapy [NPT]) shows a stratified hazard ratio of 0.71 (95% CI: 0.61-0.83, 1-sided log-rank p-value &lt; 0.0001) when CPB15+ is compared with CPP, with a median PFS of 10.4 months in the CPP arm and 14.1 months in the CPB15+ arm.
Protokolom predviđena analiza preživljenja bez progresije bolesti prema procjeni ispitivača (bez cenzuriranja za porast razine CA-125 ili terapiju izvan protokola) pokazuje stratificirani omjer rizika od 0,71 (95% CI: 0,61-0,83; p-vrijednost jednostranog log-rang testa &lt; 0,0001) kada se skupina CPB15+ usporedi sa skupinom CPP, uz medijan preživljenja bez progresije bolesti od 10,4 mjeseca u skupini CPP te 14,1 mjesec u skupini CPB15+.
The race distribution of subjects was as follows: 85% White, 12% Black, 1% Asian, &lt; 1% multiracial, &lt; 1% Native Hawaiian or Other Pacific Islander.
Raspodjela ispitanika po rasama bila je kako slijedi: 85% bijelaca, 12% crnaca, 1% Azijata, &lt; 1% miješane rase, &lt; 1% Polinežana.
The randomised phase 3 trial (0201) compared Ceplene+IL-2 treatment to no treatment in 261 patients in first remission (CR1) and in another 59 patients in subsequent remission after relapse (CR &gt; 1).
Randomizirano ispitivanje faze 3 (0201) usporedilo je liječenje Cepleneom+IL-2 s neliječenjem 261 bolesnika u prvoj remisiji (CR1) i 59 bolesnika u sljedećoj remisiji nakon relapsa (CR &gt; 1).
The rank order of dexamethasone concentration was retina &gt; iris &gt; ciliary body &gt; vitreous humour &gt; aqueous humour &gt; plasma.
Redoslijed koncentracija deksametazona bio je mrežnica &gt; šarenica &gt; zrakasto tijelo &gt; staklasto tijelo &gt; očna vodica &gt; plazma.
The rate of infusion was 2.0 microgram/kg/min for patients with serum creatinine ≤ 175 micromols/l or 1.0 microgram/kg/min for serum creatinine &gt; 175 up to 350 micromols/l.
Bolesnici s razinom serumskog kreatinina ≤ 175 mikromola/l primili su infuziju od 2,0 mikrograma/kg/min, a bolesnici s razinom serumskog kreatinina &gt; 175 do 350 mikromola/l infuziju od 1,0 mikrograma/kg/min.
The rate of mild to moderate infusion reactions was &gt; 50% in patients who were not premedicated.
Stopa blagih do umjerenih reakcija na infuziju u bolesnika koji nisu primili premedikaciju bila je &gt; 50%.
The rate of MMR at 12 months, was also statistically significantly higher for nilotinib 400 mg twice daily compared to imatinib 400 mg once daily (42.7% versus 22.3%, p &lt; 0.0001).
Stopa MMR-a u 12. mjesecu je također bila statistički značajno viša za 400 mg nilotiniba dva puta na dan u usporedbi s 400 mg imatiniba jedanput na dan (42,7% u odnosu na 22,3%, p &lt; 0,0001).
The rate of nocturnal hypoglycaemic events was significantly lower with Xultophy compared to insulin glargine (estimated treatment ratio 0.17, p &lt; 0.001).
Stopa noćnih hipoglikemijskih događaja bila je značajno niža uz Xultophy nego uz glargin inzulin (procijenjeni terapijski omjer: 0,17; p &lt; 0,001).
The rate of progression of structural damage in year 2 was significantly lower than that in year 1 for patients randomized to abatacept (p &lt; 0.0001).
Brzina napredovanja strukturnog oštećenja je za bolesnike randomizirane na abatacept bila značajno manja u 2. nego u 1. godini (p &lt; 0,0001).
The rate of the 30-day composite endpoint of death, myocardial re-infarction or intracranial haemorrhage (a measure of net clinical benefit) was significantly lower (p &lt; 0.0001) in the enoxaparin group (10.1%) as compared to the heparin group (12.2%), representing a 17% relative risk reduction in favour of treatment with enoxaparin sodium.
Stopa mjere složenog ishoda (smrt, reinfarkt miokarda ili intrakranijalno krvarenje) nakon 30 dana (mjera čiste kliničke koristi) bila je značajno niža (p &lt; 0,0001) u skupini koja je primala enoksaparin (10,1 %) u usporedbi sa skupinom koja je primala heparin (12,2 %), predstavljajući tako smanjenje relativnog rizika za 17 % u korist liječenja enoksaparinnatrijem.
The rate of the 30-day composite endpoint of death, myocardial re-infarction or intracranial haemorrhage (a measure of net clinical benefit) was significantly lower (p &lt; 0.0001) in the enoxaparin group (10.1%) as compared to the heparin group (12.2%), representing a 17% relative risk reduction in favour of treatment with enoxaparin sodium.
Stopa mjere složenog ishoda (smrt, reinfarkt miokarda ili intrakranijalno krvarenje) nakon 30 dana (mjera čiste kliničke koristi) bila je značajno niža (p &lt; 0,0001) u skupini koja je primala enoksaparin (10,1%) u usporedbi sa skupinom koja je primala heparin (12,2%), predstavljajući tako smanjenje relativnog rizika za 17% u korist liječenja enoksaparin-natrijem.
The rate of the 30-day composite endpoint of death, myocardial re-infarction or intracranial haemorrhage (a measure of net clinical benefit) was significantly lower (p &lt; 0.0001) in the enoxaparin group (10.1%) as compared to the heparin group (12.2%), representing a 17% relative risk reduction in favour of treatment with enoxaparin sodium.
Stopa mjere složenog ishoda (smrt, reinfarkt miokarda ili intrakranijalno krvarenje) nakon 30 dana (mjera čiste kliničke koristi) bila je značajno niža (p &lt; 0,0001) u skupini koja je primala enoksaparin (10,1%) u usporedbi sa skupinom koja je primala heparin (12,2%), predstavljajući tako smanjenje relativnog rizika za 17% u korist liječenja enoksaparinnatrijem.
The rate of TKV increase over 3 years was significantly less for tolvaptan-treated subjects than for subjects receiving placebo: 2.80% per year vs 5.51% per year, respectively (ratio of geometric mean 0.974; 95% CI 0.969 to 0.980; p &lt; 0.0001).
Stopa porasta UVB-a tijekom 3 godine bila je značajno manja u ispitanika liječenih tolvaptanom nego u ispitanika koji su primali placebo: 2,80% godišnje naspram 5,51% godišnje (omjer geometrijske srednje vrijednosti 0,974; 95% CI od 0,969 do 0,980; p &lt; 0,0001).
The rates and types of adverse reactions seen in the study group that received ProQuad were generally similar to those seen in the groups that received Varicella Vaccine live (Oka/Merck) and the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. (see section 5.1 for study description).
Stope i vrsta nuspojava opaženih u ispitivanoj skupini koja je primila ProQuad bile su općenito slične onima opaženima u skupinama koje su primile živo cjepivo protiv varičele (Oka/Merck) i cjepivo protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc. (vidjeti dio 5.1 za opis ispitivanja).